Effects of long-term antihypertensive therapy with losartan on blood pressure and cognitive function in patients with essential hypertension and other cerebrovascular risk factors (AWARE observational study);Effekte der antihypertensiven langzeittherapie mit losartan auf den blutdruck und die kognitive funktion bei patienten mit essentieller hypertonie und weiteren zerebrovaskulären risikofaktoren (AWARE-beobachtungsstudie)

Medizinische Klinik

Volumn 103, Issue 7, 2008, Pages 491-499

  Schrader, Jürgen ^a   Lüders, Stephan ^a   Diener, Hans Christoph ^b   Haller, Hermann ^c   Schmieder, Roland E ^d   Wahle, Klaus ^e   Smolka, Wenefrieda ^f   Jung, Claudia ^f   Bestehorn, Kurt ^f,g  

^a ST JOSEFS HOSPITAL   (Germany)

^b UNIVERSITY HOSPITAL ESSEN   (Germany)

^c HANNOVER MEDICAL SCHOOL   (Germany)

^d UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^e UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^f MSD Sharp and Dohme GmbH   (Germany)

^g DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

24 h blood pressure measurement; Arterial hypertension; Hydrochlorothiazide; Losartan; Therapy

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; C REACTIVE PROTEIN; FIBRINOGEN; LOSARTAN;

AGED; ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE MEASUREMENT; COGNITION; COGNITIVE DEFECT; DEMOGRAPHY; DIAGNOSTIC APPROACH ROUTE; DIASTOLIC BLOOD PRESSURE; ESSENTIAL HYPERTENSION; FEMALE; FIBRINOGEN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; REVIEW; RISK FACTOR; STROKE; SYSTOLIC BLOOD PRESSURE; THERAPY EFFECT; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; C-REACTIVE PROTEIN; CEREBRAL INFARCTION; DEMENTIA; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; LONG-TERM CARE; LOSARTAN; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 52249092195     PISSN: 07235003     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00063-008-1073-4     Document Type: Review

References (46)

1. Beason-Held LL, Moghekar A, Zonderman AB, et al. Longitudinal changes in cerebral blood flow in the older hypertensive brain. Stroke 2007;38:1766-73.
2. Bestehorn K, Wahle K. Impact of losartan on stroke risk in hypertensive patients in primary care. Clin Drug Investig 2007;27:347-55.
3. Brady CB, Spiro A 3rd, Gaziano JM. Effects of age and hypertension status on cognition: the Veterans Affairs Normative Aging Study. Neuropsychology 2005;19:770-7.
4. Brady CB, Spiro A 3rd, McGlinchey-Berroth R, et al. Stroke risk predicts verbal fluency decline in healthy older men: evidence from the Normative Aging Study. J Gerontol B Psychol Sci Soc Sci 2001;56:P340-6.
5. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-9.
6. Brindle P, Emberson J, Lampe F, et al. Predictive accuracy of the Framingham coronary risk score in British men: prospective cohort study. BMJ 2003;327:1267-70.
7. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003;289:2560-71.
8. c.I.-Test zur Objektivierung des Demenzverdachts. In: Lehrl S, Hrsg. Basis-System für Demenzmessung. Göttingen: Hogrefe.
9. Coca A, Sobrino J, Soler J, et al. Trough-to-peak ratio, smoothness index, and circadian blood pressure profile after treatment with once-daily fixed combination of losartan 100 and hydrochlorothiazide 25 in essential hypertension. J Cardiovasc Pharmacol 2002;39:824-33.
10. D'Agostino RB, Wolf PA, Belanger AJ, et al. Stroke risk profile: adjustment for antihypertensive medication. The Framingham Study. Stroke 1994;25:40-3.
11. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003.
12. Danesh J, Lewington S, Thompson SG, et al. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA 2005;294:1799-809.
13. Deutsche Hochdruckliga. Leitlinien zur Diagnostik und Behandlung der arteriellen Hypertonie. Nieren Hochdruckkr 2005;34:481-98.
14. Elias MF, Sullivan LM, D'Agostino RB, et al. Framingham stroke risk profile and lowered cognitive performance. Stroke 2004;35:404-9.
15. Flack JM, Saunders E, Gradman A, et al. Antihypertensive efficacy and safety of losartan alone and in combination with hydrochlorothiazide in adult African Americans with mild to moderate hypertension. Clin Ther 2001;23:1193-208.
16. Fogari R, Mugellini A, Zoppi A, et al. Influence of losartan and atenolol on memory function in very elderly hypertensive patients. J Hum Hypertens 2003;17:781-5.
17. Förster A, Smolka W, Jung C, et al. Fixkombination von Losartan/Hydrochlorothiazid 100 mg/25 mg: Verträglichkeit und Wirksamkeit auf Praxis- und 24-h-Blutdruck. MMW Fortschr Med 2007:im Druck. MMW Fortschr Med 2007;149(35-36):38.
18. Gansz A, Lüders S, Kulschewski A, et al. Improving data quality of observational studies by "on site" monitoring: interim results from the MARPLE-Project (microalbuminuria as a risk predictor in hypertension. A long-term evaluation with ramipril). Dtsch Med Wochenschr 2002;127:Suppl 1:S5-33.
19. Goa KL, Wagstaff AJ. Losartan potassium: a review of its pharmacology, clinical efficacy and tolerability in the management of hypertension. Drugs 1996;51:820-45.
20. Goldstein LB, Adams R, Alberts MJ, et al. Primary prevention of ischemic stroke. A guideline from the American Heart Association/American Stroke Association Stroke Council. Stroke 2006:01. STR.0000223048.70103.F1. Stroke 2006, 37(6):1583-633.
21. Gradman AH, Brady WE, Gazdick LP, et al. A multicenter, randomized, double-blind, placebo-controlled, 8-week trial of the efficacy and tolerability of once-daily losartan 100 mg/hydrochlorothiazide 25 mg and losartan 50 mg/hydro chlorothiazide 12.5 mg in the treatment of moderate-to-severe essential hypertension. Clin Ther 2002;24:1049-61.
22. Hajjar I, Keown M, Frost B. Antihypertensive agents for aging patients who are at risk for cognitive dysfunction. Curr Hypertens Rep 2005;7:466-73.
23. Jennings JR, Muldoon MF, Ryan C, et al. Reduced cerebral blood flow response and compensation among patients with untreated hypertension. Neurology 2005;64:1358-65.
24. Kilander L, Nyman H, Boberg M, et al. Hypertension is related to cognitive impairment: a 20-year follow-up of 999 men. Hypertension 1998;31:780-6.
25. Kizer JR, Dahlof B, Kjeldsen SE, et al. Stroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan versus atenolol: the Losartan Intervention For Endpoint reduction in hypertension study. Hypertension 2005;45:46-52.
26. Kuo HK, Yen CJ, Chang CH, et al. Relation of C-reactive protein to stroke, cognitive disorders, and depression in the general population: systematic review and meta-analysis. Lancet Neurol 2005;4:371-80.
27. Launer LJ, Masaki K, Petrovitch H, et al. The association between midlife blood pressure levels and late-life cognitive function. The Honolulu-Asia Aging Study. JAMA 1995;274:1846-51.
28. Law MR, Wald NJ, Morris JK, et al. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 2003;326:1427-30.
29. MacMahon S, Peto R, Cutler J, et al. Blood pressure, stroke, and coronary heart disease. Part 1: Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990;335:765-74.
30. Mancia G, De Backer G, Dominiczak A, et al. 2007 guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007;28:1462-536.
31. Meister W. Die Anwendungsbeobachtung - eine Beobachtung der Anwendung. Dtsch Med Wochenschr 2003;128:859-62.
32. Moen MD, Wagstaff AJ. Losartan: a review of its use in stroke risk reduction in patients with hypertension and left ventricular hypertrophy. Drugs 2005;65:2657-74.
33. Naidoo DP, Sareli P, Marin F, et al. Increased efficacy and tolerability with losartan plus hydrochlorothiazide in patients with uncontrolled hypertension and therapy-related symptoms receiving two monotherapies. Adv Ther 1999;16:187-99.
34. Oparil S, Aurup P, Snavely D, et al. Efficacy and safety of losartan/hydrochlorothiazide in patients with severe hypertension. Am J Cardiol 2001;87:721-6.
35. Pittrow D, Stalla GK, Zeiher AM, et al. Prävalenz, medikamentöse Behandlung und Einstellung des Diabetes mellitus in der Hausarztpraxis. Med Klin 2006;101:635-44.
36. Ruilope LM, Segura J. Losartan and other angiotensin II antagonists for nephropathy in type 2 diabetes mellitus: a review of the clinical trial evidence. Clin Ther 2003;25:3044-64.
37. Salerno CM, Demopoulos L, Mukherjee R, et al. Combination angiotensin receptor blocker/hydrochlorothiazide as initial therapy in the treatment of patients with severe hypertension. J Clin Hypertens (Greenwich) 2004;6:614-20.
38. Simpson KL, McClellan KJ. Losartan: a review of its use, with special focus on elderly patients. Drugs Aging 2000;16:227-50.
39. Skoog I, Lernfelt B, Landahl S, et al. 15-year longitudinal study of blood pressure and dementia. Lancet 1996;347:1141-5.
40. Smith SC Jr, Allen J, Blair SN, et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation 2006;113:2363-72.
41. Soffer BA, Wright JT Jr, Pratt JH, et al. Effects of losartan on a background of hydrochlorothiazide in patients with hypertension. Hypertension 1995;26:112-7.
42. Tedesco MA, Ratti G, Mennella S, et al. Comparison of losartan and hydrochlorothiazide on cognitive function and quality of life in hypertensive patients. Am J Hypertens 1999;12:1130-4.
43. Tzoulaki I, Murray GD, Lee AJ, et al. Relative value of inflammatory, hemostatic, and rheological factors for incident myocardial infarction and stroke: the Edinburgh Artery Study. Circulation 2007;115:2119-27.
44. Van Dijk EJ, Breteler MM, Schmidt R, et al. The association between blood pressure, hypertension, and cerebral white matter lesions: cardiovascular determinants of dementia study. Hypertension 2004;44:625-30.
45. Vermeer SE, Hollander M, van Dijk EJ, et al. Silent brain infarcts and white matter lesions increase stroke risk in the general population: the Rotterdam Scan Study. Stroke 2003;34:1126-9.
46. Vermeer SE, Prins ND, den Heijer T, et al. Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med 2003;348:1215-22.